NTV Asset Management LLC Has $272,000 Stake in Astrazeneca PLC (AZN)
NTV Asset Management LLC maintained its position in Astrazeneca PLC (NYSE:AZN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,000 shares of the company’s stock at the end of the second quarter. NTV Asset Management LLC’s holdings in Astrazeneca PLC were worth $272,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. TIAA CREF Trust Co. FSB MO acquired a new stake in Astrazeneca PLC during the first quarter valued at about $544,000. Genesee Valley Trust Co. raised its stake in Astrazeneca PLC by 1.8% in the first quarter. Genesee Valley Trust Co. now owns 7,465 shares of the company’s stock valued at $232,000 after buying an additional 130 shares during the last quarter. First Trust Advisors LP raised its stake in Astrazeneca PLC by 2.1% in the first quarter. First Trust Advisors LP now owns 559,130 shares of the company’s stock valued at $17,411,000 after buying an additional 11,548 shares during the last quarter. Wrapmanager Inc. raised its stake in Astrazeneca PLC by 86.5% in the first quarter. Wrapmanager Inc. now owns 43,310 shares of the company’s stock valued at $1,349,000 after buying an additional 20,087 shares during the last quarter. Finally, Eqis Capital Management Inc. raised its stake in Astrazeneca PLC by 6.2% in the first quarter. Eqis Capital Management Inc. now owns 16,942 shares of the company’s stock valued at $528,000 after buying an additional 993 shares during the last quarter. 14.18% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE AZN) opened at 29.44 on Tuesday. The company has a market capitalization of $74.54 billion, a P/E ratio of 19.31 and a beta of 0.74. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a 50-day moving average of $31.08 and a 200-day moving average of $31.53.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same quarter last year, the firm posted $0.83 earnings per share. The business’s revenue for the quarter was down 9.9% compared to the same quarter last year. Equities analysts expect that Astrazeneca PLC will post $1.86 EPS for the current fiscal year.
The company also recently declared a None dividend, which will be paid on Monday, September 11th. Investors of record on Friday, August 11th will be paid a $0.44 dividend. The ex-dividend date is Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s dividend payout ratio is currently 44.92%.
ILLEGAL ACTIVITY WARNING: “NTV Asset Management LLC Has $272,000 Stake in Astrazeneca PLC (AZN)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/29/ntv-asset-management-llc-has-272000-stake-in-astrazeneca-plc-azn.html.
Several research firms have issued reports on AZN. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Cowen and Company restated a “hold” rating and set a $34.00 price target on shares of Astrazeneca PLC in a research report on Friday, July 28th. Morgan Stanley lowered shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, July 28th. Finally, Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Astrazeneca PLC currently has an average rating of “Hold” and an average target price of $33.39.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.